Get to know Tafamidis better with 2 real example sentences, the meaning.
Tafamidis in a sentence
Tafamidis meaning
A drug for the amelioration of transthyretin-related hereditary amyloidosis.
Using Tafamidis
- The main meaning on this page is: A drug for the amelioration of transthyretin-related hereditary amyloidosis.
Context around Tafamidis
- Average sentence length in these examples: 23 words
- Position in the sentence: 1 start, 1 middle, 0 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Tafamidis
- In this selection, "tafamidis" usually appears near the start of the sentence. The average example has 23 words, and this corpus slice is mostly made up of statements.
- Around the word, receives stand out and add context to how "tafamidis" is used.
- Recognizable usage signals include if tafamidis receives fda and use of tafamidis or vyndaqel. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "tafamidis" sits close to words such as aabb, aabria and aacha, which helps place it inside the broader word index.
Example types with tafamidis
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
If tafamidis receives FDA approval for transthyretin amyloid cardiomyopathy, it would be the first medical therapy for this life-threatening disease. (21 words)
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases. (25 words)
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases. (25 words)
If tafamidis receives FDA approval for transthyretin amyloid cardiomyopathy, it would be the first medical therapy for this life-threatening disease. (21 words)
Example sentences (2)
If tafamidis receives FDA approval for transthyretin amyloid cardiomyopathy, it would be the first medical therapy for this life-threatening disease.
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases.